Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

Qian Xie, Robert Bradley, Liang Kang, Julie Koeman, Maria Libera Ascierto, Andrea Worschech, Valeria De Giorgi, Ena Wang, Lisa Kefene, Yanli Su, Curt Essenburg, Dafna W. Kaufman, Tom DeKoning, Mark A. Enter, Timothy J. O'Rourke, Francesco M. Marincola, George F. Vande Woude

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies. We investigated in vivo glioblastoma models characterized by hepatocyte growth factor (HGF) autocrine or paracrine activation, or by MET or EGFR amplification, for their susceptibility to MET inhibitors. HGF autocrine expression correlated with high phospho-MET levels in HGF autocrine cell lines, and these lines showed high sensitivity to MET inhibition in vivo. An HGF paracrine environment may enhance glioblastoma growth in vivo but did not indicate sensitivity to MET inhibition. EGFRvIII amplification predicted sensitivity to EGFR inhibition, but in the same tumor, increased copies of MET from gains of chromosome 7 did not result in increased MET activity and did not predict sensitivity to MET inhibitors. Thus, HGF autocrine glioblastoma bears an activated MET signaling pathway that may predict sensitivity to MET inhibitors. Moreover, serum HGF levels may serve as a biomarker for the presence of autocrine tumors and their responsiveness to MET therapeutics.

Original languageEnglish
Pages (from-to)570-575
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume109
Issue number2
DOIs
Publication statusPublished - 10 Jan 2012
Externally publishedYes

Fingerprint

Hepatocyte Growth Factor
Glioblastoma
Epidermal Growth Factor Receptor
Neoplasms
Chromosomes, Human, Pair 7
Oncogenes
Biomarkers
Cell Line
Therapeutics
Growth
Serum

Keywords

  • Hepatocyte growth factor-autocrine loop
  • Molecular marker
  • Oncogene addiction
  • Targeted therapy

ASJC Scopus subject areas

  • General

Cite this

Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. / Xie, Qian; Bradley, Robert; Kang, Liang; Koeman, Julie; Ascierto, Maria Libera; Worschech, Andrea; De Giorgi, Valeria; Wang, Ena; Kefene, Lisa; Su, Yanli; Essenburg, Curt; Kaufman, Dafna W.; DeKoning, Tom; Enter, Mark A.; O'Rourke, Timothy J.; Marincola, Francesco M.; Vande Woude, George F.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, No. 2, 10.01.2012, p. 570-575.

Research output: Contribution to journalArticle

Xie, Q, Bradley, R, Kang, L, Koeman, J, Ascierto, ML, Worschech, A, De Giorgi, V, Wang, E, Kefene, L, Su, Y, Essenburg, C, Kaufman, DW, DeKoning, T, Enter, MA, O'Rourke, TJ, Marincola, FM & Vande Woude, GF 2012, 'Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma', Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 2, pp. 570-575. https://doi.org/10.1073/pnas.1119059109
Xie, Qian ; Bradley, Robert ; Kang, Liang ; Koeman, Julie ; Ascierto, Maria Libera ; Worschech, Andrea ; De Giorgi, Valeria ; Wang, Ena ; Kefene, Lisa ; Su, Yanli ; Essenburg, Curt ; Kaufman, Dafna W. ; DeKoning, Tom ; Enter, Mark A. ; O'Rourke, Timothy J. ; Marincola, Francesco M. ; Vande Woude, George F. / Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. In: Proceedings of the National Academy of Sciences of the United States of America. 2012 ; Vol. 109, No. 2. pp. 570-575.
@article{ecbf43a5675f4c0592b7837f4e9c43a5,
title = "Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma",
abstract = "Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies. We investigated in vivo glioblastoma models characterized by hepatocyte growth factor (HGF) autocrine or paracrine activation, or by MET or EGFR amplification, for their susceptibility to MET inhibitors. HGF autocrine expression correlated with high phospho-MET levels in HGF autocrine cell lines, and these lines showed high sensitivity to MET inhibition in vivo. An HGF paracrine environment may enhance glioblastoma growth in vivo but did not indicate sensitivity to MET inhibition. EGFRvIII amplification predicted sensitivity to EGFR inhibition, but in the same tumor, increased copies of MET from gains of chromosome 7 did not result in increased MET activity and did not predict sensitivity to MET inhibitors. Thus, HGF autocrine glioblastoma bears an activated MET signaling pathway that may predict sensitivity to MET inhibitors. Moreover, serum HGF levels may serve as a biomarker for the presence of autocrine tumors and their responsiveness to MET therapeutics.",
keywords = "Hepatocyte growth factor-autocrine loop, Molecular marker, Oncogene addiction, Targeted therapy",
author = "Qian Xie and Robert Bradley and Liang Kang and Julie Koeman and Ascierto, {Maria Libera} and Andrea Worschech and {De Giorgi}, Valeria and Ena Wang and Lisa Kefene and Yanli Su and Curt Essenburg and Kaufman, {Dafna W.} and Tom DeKoning and Enter, {Mark A.} and O'Rourke, {Timothy J.} and Marincola, {Francesco M.} and {Vande Woude}, {George F.}",
year = "2012",
month = "1",
day = "10",
doi = "10.1073/pnas.1119059109",
language = "English",
volume = "109",
pages = "570--575",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "2",

}

TY - JOUR

T1 - Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma

AU - Xie, Qian

AU - Bradley, Robert

AU - Kang, Liang

AU - Koeman, Julie

AU - Ascierto, Maria Libera

AU - Worschech, Andrea

AU - De Giorgi, Valeria

AU - Wang, Ena

AU - Kefene, Lisa

AU - Su, Yanli

AU - Essenburg, Curt

AU - Kaufman, Dafna W.

AU - DeKoning, Tom

AU - Enter, Mark A.

AU - O'Rourke, Timothy J.

AU - Marincola, Francesco M.

AU - Vande Woude, George F.

PY - 2012/1/10

Y1 - 2012/1/10

N2 - Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies. We investigated in vivo glioblastoma models characterized by hepatocyte growth factor (HGF) autocrine or paracrine activation, or by MET or EGFR amplification, for their susceptibility to MET inhibitors. HGF autocrine expression correlated with high phospho-MET levels in HGF autocrine cell lines, and these lines showed high sensitivity to MET inhibition in vivo. An HGF paracrine environment may enhance glioblastoma growth in vivo but did not indicate sensitivity to MET inhibition. EGFRvIII amplification predicted sensitivity to EGFR inhibition, but in the same tumor, increased copies of MET from gains of chromosome 7 did not result in increased MET activity and did not predict sensitivity to MET inhibitors. Thus, HGF autocrine glioblastoma bears an activated MET signaling pathway that may predict sensitivity to MET inhibitors. Moreover, serum HGF levels may serve as a biomarker for the presence of autocrine tumors and their responsiveness to MET therapeutics.

AB - Because oncogene MET and EGF receptor (EGFR) inhibitors are in clinical development against several types of cancer, including glioblastoma, it is important to identify predictive markers that indicate patient subgroups suitable for such therapies. We investigated in vivo glioblastoma models characterized by hepatocyte growth factor (HGF) autocrine or paracrine activation, or by MET or EGFR amplification, for their susceptibility to MET inhibitors. HGF autocrine expression correlated with high phospho-MET levels in HGF autocrine cell lines, and these lines showed high sensitivity to MET inhibition in vivo. An HGF paracrine environment may enhance glioblastoma growth in vivo but did not indicate sensitivity to MET inhibition. EGFRvIII amplification predicted sensitivity to EGFR inhibition, but in the same tumor, increased copies of MET from gains of chromosome 7 did not result in increased MET activity and did not predict sensitivity to MET inhibitors. Thus, HGF autocrine glioblastoma bears an activated MET signaling pathway that may predict sensitivity to MET inhibitors. Moreover, serum HGF levels may serve as a biomarker for the presence of autocrine tumors and their responsiveness to MET therapeutics.

KW - Hepatocyte growth factor-autocrine loop

KW - Molecular marker

KW - Oncogene addiction

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84855993422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855993422&partnerID=8YFLogxK

U2 - 10.1073/pnas.1119059109

DO - 10.1073/pnas.1119059109

M3 - Article

VL - 109

SP - 570

EP - 575

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 2

ER -